Evidence map›Paper›PMID 35590418›Full record

ArticleJournal of translational medicine2022

Bulk and single-cell transcriptome profiling reveal necroptosis-based molecular classification, tumor microenvironment infiltration characterization, and prognosis prediction in colorectal cancer.

Wenqin Luo, Wenqiang Xiang, Lu Gan, Ji Che, Jing Li, Yichao Wang, Lingyu Han, Ruiqi Gu, Li Ye, Renjie Wang and 6 more

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 1 country.

Wenqin Luo *Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Wenqiang Xiang *Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Lu Gan *Department of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, China.
Ji Che *Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Jing LiDepartment of CyberKnife Center, Huashan Hospital, Fudan University, Shanghai, China.
Yichao WangDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Lingyu HanDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Ruiqi GuDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Li YeDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Renjie WangDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Xiuping ZhangXiamen Clinical Research Center for Cancer Therapy, Xiamen Branch, Zhongshan Hospital, Fudan University, Xiamen, China.
Ye XuDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China.
Weixing DaiDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. daiweixing2015@163.com.
Shaobo MoDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. shaobom@126.com.
Qingguo LiDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. oncosurgeonli@sohu.com.
Guoxiang CaiDepartment of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, China. gxcaifuscc@163.com.
Shanghai Medical College of Fudan University · CNFudan University Shanghai Cancer Center · CNHuashan Hospital · CNZhongshan Hospital · CNZhongshan Hospital of Xiamen University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNecroptosis is a new form of programmed cell death that is associated with cancer initiation, progression, immunity, and chemoresistance. However, the roles of necroptosis-related genes (NRGs) in colorectal cancer (CRC) have not been explored comprehensively.

methodsIn this study, we obtained NRGs and performed consensus molecular subtyping by "ConsensusClusterPlus" to determine necroptosis-related subtypes in CRC bulk transcriptomic data. The ssGSEA and CIBERSORT algorithms were used to evaluate the relative infiltration levels of different cell types in the tumor microenvironment (TME). Single-cell transcriptomic analysis was performed to confirm classification related to NRGs. NRG_score was developed to predict patients' survival outcomes with low-throughput validation in a patients' cohort from Fudan University Shanghai Cancer Center.

resultsWe identified three distinct necroptosis-related classifications (NRCs) with discrepant clinical outcomes and biological functions. Characterization of TME revealed that there were two stable necroptosis-related phenotypes in CRC: a phenotype characterized by few TME cells infiltration but with EMT/TGF-pathways activation, and another phenotype recognized as immune-excluded. NRG_score for predicting survival outcomes was established and its predictive capability was verified. In addition, we found NRCs and NRG_score could be used for patient or drug selection when considering immunotherapy and chemotherapy.

conclusionsBased on comprehensive analysis, we revealed the potential roles of NRGs in the TME, and their correlations with clinicopathological parameters and patients' prognosis in CRC. These findings could enhance our understanding of the biological functions of necroptosis, which thus may aid in prognosis prediction, drug selection, and therapeutics development.

Indexed as

Colorectal NeoplasmsTumor MicroenvironmentBiomarkers, TumorChinaGene Expression ProfilingGene Expression Regulation, NeoplasticHumansNecroptosisPrognosisTranscriptomeBiomarkers, TumorColorectal cancerDrug sensitivityImmunotherapyNecroptosisTumor microenvironment

Identifiers

PMID35590418
PMCPMC9118791
OpenAlexW4280555969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.